Petya Kraleva

Impact of structured oncologist-led home visits on psychological distress and resilience in patients with solid tumors undergoing chemotherapy: A comparative study.

Sonya Kircheva Draganova, Radostina Gencheva, Mariyana Eneva, Petya Kraleva et autres

12089 Background: Psychological distress is prevalent among patients receiving chemotherapy. Home-based supportive interventions have the potential to address early psychosocial needs; however, data regarding their impact on both distress and resilience remain limited. Methods: Between March 1 and December 1, 2025, chemotherapy-naïve …

bg (code pays fourni par la source)

Effect of a single home visit on distress in cancer patients undergoing chemotherapy: A comparative study.

Mila Petrova, Sonya Kircheva Draganova, Rosalina Pechlivanova, Mariyana Eneva et autres

12107 Background: This study aimed to investigate whether a home visit after the first chemotherapy can significantly reduce cancer patients’ psychological distress levels. Methods: The National Comprehensive Cancer Network Distress Thermometer and problem list was used to assess patients’ level of distress …

bg (code pays fourni par la source)

30 Validation of the clinical practicability of the GPA for NSCLC patients with BMs treated with GKRS.

K. Zhelev, Manoela Krasteva Cholakova, Bilyana Georgieva Korabova, Maria Mihaylova-Hristova et autres

28 KRAS status as an independent prognostic factor for survival after SBRT Colorectal Cancer Liver Metastases

Manoela Krasteva Cholakova, K. Zhelev, Maria Mihaylova-Hristova, Iglika Mihaylova et autres

Prevalence and prognosis of PIK3CA mutations in Bulgarian patients with metastatic breast cancer receiving endocrine therapy in first‐line setting

R. Gencheva, Mirela Petrova, Petya Kraleva, Savina Petrova Hadjidekova et autres

BACKGROUND AND AIMS: In approximately 40% of patients with HER2-negative/HR-positive breast cancer tumors, the PIK3CA gene is mutated. Despite this, clinical outcomes vary between studies in this cohort. We aimed to ascertain the prevalence of PIK3CA mutations in patients with metastatic HR+/HER2- …

bg (code pays fourni par la source)

Patient resilience and distress level prior to chemotherapy based on time estimation.

Petya Kraleva, Mila Petrova, Todor A. Popov, Nikolay Vladimirov Conev et autres

e24184 Background: Our prospective and multicentric study aimed to determine if the effects of breast cancer patients' resilience on their distress levels are mediated by the assessment of time before initiating neo/adjuvant chemotherapy. Methods: In 104 chemo-naive breast cancer patients, time estimation …

bg (code pays fourni par la source)

PI3KCA mutation prevalence and outcome among patients with metastatic breast cancer in Bulgaria treated with first-line endocrine therapy.

Radostina Gencheva, Savina Petrova Hadjidekova, Mila Petrova, D Krŭstev et autres

e13005 Background: There are phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations in 30-40% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) tumor samples. Nevertheless, clinical outcomes in this group vary amongst research trials. Methods: We sought to determine …

bg (code pays fourni par la source)

Tumor neutrophil extracellular traps and pretreatment neutrophils in association with progression-free survival in patients with metastatic non-small cell lung cancer receiving pembrolizumab alone or with chemotherapy.

Mila Petrova, Dimiter Parvanov, Rumiana Ganeva, Dimiter Metodiev et autres

e21099 Background: Background: In this multicentric retrospective study, we evaluated the relationship between pre- treatment blood neutrophils and neutrophil extracellular traps (NET) in biopsy samples and their predictive value for progression progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) receiving …

bg (code pays fourni par la source)